港股異動 | 億勝生物科技(1061.HK)逆勢大漲逾16% 股價創8個月新高
格隆匯3月2日丨億勝生物科技(1061.HK)逆勢拉昇16.6%,報5.48港元創8個月新高價,總市值31.6億港元。日前公司與Mitotech共同開發用於乾眼症、含SkQ1之滴眼液美國藥監局第二階段三期試驗取得正面結果。Mitotech目標於2022-2023年完成新藥申請提交。在此前生物醫藥股港股大牛市的背景下,億勝生物科技走勢相對平淡,在近日大市回調的背景下股價異常活躍。值得一提的是,2月24日,港府計劃印花税,引發市場暴跌,但公司卻逆勢大漲14%,今日香港財政司司長陳茂波稱不排除進一步提高股票印花税,又導致市場大跌,公司再次逆勢拉昇。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.